Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
With
Viewray Inc.
Progenics Pharmaceuticals, Inc.
This study is a randomized non-inferiority trial comparing 5 to 2 radiotherapy treatments using an MRI linear accelerator for men with low or intermediate-risk prostate cancer electing for definitive radiotherapy.
Age
18–90
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men aged \>=18 with histologically confirmed low or intermediate risk prostate cancer per NCCN guidelines.
ECOG 0 - 1
IPSS \< 18
Ability to receive MRI-guided radiotherapy.
Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.
Patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the Principal Investigator.
You may not be if
Prior history of receiving pelvic radiotherapy.
Patient with history of inflammatory bowel disease.
MRI Prostate Volume \> 80 cc
MRI Stage \> T3a
Unilateral or bilateral hip replacements.
History of bladder neck or urethral stricture.
TURP \< 8 weeks prior to radiotherapy
Metastatic (pelvic nodal or distant) disease on CT, Bone, Fluciclovine, and/or PSMA PET scan
Clareo Health | Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
